Kratom vs. 7-OH: why the concentrated version grips harder

At a glance: kratom leaf vs. concentrated 7-OH

Key Takeaways

• Same plant, different drug. Kratom leaf is mostly mitragynine, a partial opioid agonist. 7-OH is a trace compound concentrated via chemical synthesis to levels the plant never reaches on its own.
• The potency gap is large. The FDA's 2025 scientific assessment documented that 7-OH produces respiratory depression at more than three times the potency of morphine. Preclinical receptor binding studies show even higher affinity at the mu-opioid receptor.
• The leaf has a partial brake; the concentrate does not. Mitragynine's partial agonism limits how high the opioid effect can go. Concentrated 7-OH pushes past that margin, producing dose-dependent respiratory depression more like classical opioids.
• Dependence builds faster with the concentrate. Stronger receptor activation drives faster neuroadaptation, so tolerance and physical dependence form in days to weeks rather than the longer arc typical of leaf use.
• Regulators drew the same line pharmacology would. The federal action targets above-threshold concentrated products and explicitly spares botanical leaf, because the evidence distinguishes them.

Mitragynine vs. 7-hydroxymitragynine: plain-language

The kratom plant contains dozens of alkaloids. Mitragynine is by far the dominant one, making up roughly 60 to 70% of the total alkaloid content in dried leaf. It is the compound responsible for most of what traditional kratom users experience.

7-Hydroxymitragynine is a minor alkaloid. In fresh kratom leaves, it is barely detectable. In dried, post-harvest leaf, it appears at concentrations of 0.003% to 0.04% by weight. It is an oxidative byproduct that forms during drying, not a compound the living plant produces in meaningful amounts.

Per molecule, however, 7-OH is far more potent than mitragynine at opioid receptors. It binds more tightly and activates more strongly.

There is also a metabolic dimension: the body converts some mitragynine into 7-OH through liver enzyme activity. In traditional kratom leaf use, some of the opioid effect comes from this internal conversion rather than from 7-OH in the leaf itself. This conversion happens gradually, in limited amounts, subject to normal metabolic regulation.

Mitragynine is kratom's main, milder alkaloid. 7-OH is a trace alkaloid many times more potent per molecule, which is why concentrating it changes the drug entirely.

How 7-OH products concentrate the opioid compound

Commercial concentrated 7-OH products are not made by extracting large amounts of 7-OH from the kratom plant. That would require processing an impractical volume of plant material, since the leaf contains so little. Instead, manufacturers isolate mitragynine, then chemically oxidize it into 7-OH in a laboratory setting.

A peer-reviewed analysis published in the Journal of Analytical Toxicology examined commercial products labeled as "kratom extract" and found 7-OH concentrations of 22 to 75 milligrams per gram. The researchers concluded these levels were "achievable only by synthetic means." The chromatographic profiles were inconsistent with natural kratom leaf: the other alkaloids that occur naturally in the plant were absent, and chemical artifacts of the oxidation process were present.

The 2025 Pharmaceutical Biology comprehensive review (Alsbrook, Pro, and Koturbash) made the same distinction: traditional kratom preparations are mitragynine-dominant with trace 7-OH formed in the body; concentrated 7-OH products deliver a direct mu-opioid receptor agonist at concentrations far beyond anything botanical.

The federal threshold of 0.05% 7-OH by dry weight (and more than 1 mg per article for synthetic products) was specifically chosen to sit between natural kratom concentrations and what manufactured products contain. Virtually all commercial tablets, gummies, and shots fall above it.

Related compounds that do not occur in the plant at all, mitragynine pseudoindoxyl (MP), MGM-15, and MGM-16, have also appeared in products marketed as kratom extracts and are being scheduled alongside 7-OH.

Why the concentrate produces stronger dependence and more risk

The ceiling, and losing it. A key feature of mitragynine at the mu-opioid receptor is partial agonism. It activates the receptor incompletely compared to full agonists like morphine. Research also suggests mitragynine may preferentially activate G-protein signaling pathways over the beta-arrestin pathway associated with respiratory depression, though this is an active research area. Together, these properties create a ceiling: at some point, more mitragynine does not keep increasing opioid effect, and the respiratory depression risk is bounded.

Concentrated 7-OH does not carry the same ceiling. The FDA's 2025 assessment documented dose-dependent respiratory depression from 7-OH without an equivalent limiting mechanism. A peer-reviewed 2025 pharmacology study confirmed that 7-OH produces respiratory depression reversible with naloxone, consistent with classical opioid pharmacology. More product means more opioid effect on breathing, without a natural brake.

The dependence differential. Stronger, more complete mu-opioid receptor activation drives faster neuroadaptation. The brain responds to the consistent opioid signal by downregulating receptor sensitivity, which establishes physical dependence. With 7-OH's higher potency, this process can occur within days to weeks of regular use, faster than the typical arc with leaf-based mitragynine use.

The DEA's own assessment in the July 2026 notices described 7-OH as sharing a pharmacological profile with Schedule II opioids, with abuse potential, tolerance, dependence, and respiratory depression comparable to classical opioid painkillers.

The escalation loop. Leaf kratom's ceiling tends to interrupt the dose-escalation cycle at some point. When more product stops producing more effect, the motivation to keep adding declines. Concentrated 7-OH has no equivalent interrupt. As tolerance builds, more tablets produce more receptor activation, and the effect resumes, for a while, before the next tolerance increase. This is the pattern that drives escalating use and deepens dependence faster.

The honest framing: This comparison rests on receptor pharmacology, potency data, preclinical work, the FDA's 2025 scientific assessment, and regulatory review. It does not rest on head-to-head human addiction trials comparing leaf to concentrate, which have not been conducted. The pharmacological reasoning is strong; the claim is not that clinical trials proved it but that the evidence is consistent and has persuaded major regulatory agencies to act on it.

Signs that 7-OH use has become a problem

The escalation with concentrated 7-OH is often faster than people expect. Signs the product has taken hold:

• Needing more tablets for the same effect than a few weeks ago
• Dosing on a schedule to avoid feeling bad rather than to feel good
• Noticing withdrawal-like symptoms (anxiety, muscle aches, restlessness) between doses
• Quiet failed attempts to skip a day or cut back
• Spending more money on products than intended
• Hiding use from people in your life

"It got away from me fast" is the norm with concentrated 7-OH, not an exception. A product engineered to be many times stronger than the plant, with no regulatory ceiling on concentration, produced a predictable result. This is the product working as designed, not a willpower failure.

For more on the hidden nature of this pattern, see The Hidden Habit: Why 7-OH Addiction Is Easier to Hide.

How dependence on 7-OH is treated

Because 7-OH dependence runs through mu-opioid receptors, buprenorphine/naloxone (Suboxone) addresses it through the same mechanism as any opioid use disorder. Buprenorphine is a high-affinity partial agonist at the same receptors, which is why it stabilizes withdrawal and cravings. A 2026 AIM Clinical Cases paper in Annals of Internal Medicine describes buprenorphine as the preferred treatment for 7-OH and kratom dependence.

Switching to kratom leaf is not a taper. It maintains opioid receptor dependence in a milder form. The same withdrawal eventually arrives when the leaf is stopped. See Can You Switch from 7-OH Back to Kratom Powder?.

Buprenorphine treatment is accessible through telehealth in most states, often the same day. See how Bicycle Health's treatment works.

Frequently Asked Questions

Is 7-OH stronger than kratom?

Yes, significantly. 7-OH binds mu-opioid receptors with higher affinity than mitragynine and activates them more fully. The FDA's 2025 scientific assessment documented respiratory depression at more than three times morphine's potency. Kratom leaf's primary alkaloid, mitragynine, produces a partial opioid effect with a ceiling that limits its respiratory risk. Concentrated 7-OH does not have an equivalent ceiling.

Why does 7-OH cause dependence faster than kratom leaf?

Stronger, more complete opioid receptor activation drives faster neuroadaptation. When the receptor is consistently activated at higher levels, the brain downregulates receptor sensitivity more quickly, establishing physical dependence faster. With concentrated 7-OH products at commercial doses, tolerance and dependence can develop within days to weeks of regular use. With leaf-based mitragynine, this process is slower, partly because the partial agonism ceiling limits sustained high-level activation.

Is kratom leaf safe because it is milder than 7-OH?

No. "Milder" describes the pharmacological comparison, not a safety rating. Kratom leaf causes real physical dependence, documented withdrawal, potential liver injury in some users, and other health risks. The comparison with 7-OH is a relative one: leaf has features that reduce certain risks compared to the concentrate. That is not an endorsement of leaf kratom as safe. See Why Kratom Causes Real Physical Dependence.

Why did regulators ban 7-OH but not kratom leaf?

The DEA's July 2026 notices of intent explicitly target 7-OH above a 0.05% threshold and three synthetic derivatives, while stating the action does not apply to botanical kratom products below that threshold. This reflects the pharmacological distinction: concentrated 7-OH products pose the overdose, dependence, and potency risks that drove the regulatory action, while natural leaf at trace concentrations does not carry the same profile. Several states have separately chosen to ban all kratom including leaf under their own laws.

Can buprenorphine treat 7-OH dependence?

Yes. Buprenorphine stabilizes the mu-opioid receptors that 7-OH activates, preventing withdrawal and reducing cravings. It is the evidence-based preferred treatment for 7-OH and kratom dependence per published clinical guidance. It is available through telehealth in most states. See how to access it.